The publicly traded company said that exploring the US market had been one of Acme's most ambitious projects, which will generate yearly earnings of $50,000 approximately
The Acme Laboratories Limited, a local pharmaceutical company, on Thursday announced that they launched Zolpidem, a tablet used to treat sleep disorder, in the US market through contact manufacturing.
The publicly traded company said that exploring the US market had been one of Acme's most ambitious projects, which will generate yearly earnings of $50,000 approximately.
According to an official disclosure posted on the Dhaka Stock Exchange (DSE) website on the day, the Zolpidem tablets are sold in 5mg. and 10mg doses.
Meanwhile, Acme Laboratories' board of directors had recommended a 25% cash dividend for the year ended on June 30, 2020.
The annual general meeting will be held on December 10 at 11:30am through a digital platform. The record date is November 10.
The company has also reported earnings per share (EPS) of Tk6.85, net asset value (NAV) per share of Tk90 and NOCFPS of Tk5.42 for the year ended on June 30, 2020 as against Tk6.81, Tk86.69 and Tk7.81 respectively for the same period of the previous year.
It is presently an 'A' category company, and was listed on the country's bourses in 2016.
The share price of Acme Laboratories closed at Tk 69.40 each on the DSE on Thursday. The company’s paid-up capital is Tk211 crore.
The Acme Laboratories are currently producing more than 500 products in different dosage forms covering broader therapeutic categories which include anti-infective, cardiovascular, anti-diabetics, gastrointestinal, CNS, respiratory disease etc. among many others.
The sponsor-directors own 41.54% stake in the company, institutional investors 31.45%, foreign investors 0.13% and the general public 26.87% as of July 31, 2020.